Login / Signup

Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.

Yawara KawanoHiroyuki HataSeiji TakashioKenichi TsujitaMitsuharu UedaMasao Matsuoka
Published in: British journal of haematology (2022)
Keyphrases
  • newly diagnosed
  • multiple myeloma
  • end stage renal disease
  • ejection fraction
  • low dose
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes